Recruiting

Cancer Genome Sequencing

Sponsor:

New Mexico Cancer Research Alliance

Code:

NCT06207864

Conditions

Malignant Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Return of Results

Survey Administration

Study Details

Brief summary:

This clinical trial studies engagement strategies for recruiting American Indians (AI) of Southwestern Tribal Nations for cancer genome sequencing. American Indians in the Southwest have higher rates of some types of cancer, such as cancers that arise in the liver, kidney, breast, and colon. American Indians with cancer may also live for less time than people from other population groups who have been treated for the same cancer. Damage to the cells of the body, acquired as people live, grow older, and are exposed to the environment, causes genetic changes in cells that can lead to cancer. This study may help researchers learn how these genetic changes in cells cause cancer and understand how and why cancer is arising in American Indians in the Southwest. This may help better prevent and treat cancer in the future.

Conditions

Malignant Neoplasm

Study ID

NCT06207864

Start date

Mar 22, 2022

Status verified date

May, 2025

Completion date

Dec 31, 2030

Anticipated

Primary completion date

Dec 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • The PE-CGS Research Center is only recruiting and sequencing tumors for adult-onset cancers (patients and survivors) among the American Indian Tribes, Nations, and Pueblos of New Mexico and adjacent states
  • Male or female adults (18 years) or older
  • Cancer patient undergoing active treatment or a cancer survivor
  • Self-identify as American Indian

Exclusion Criteria:

  • Cognitively impaired
  • Adults unable to consent for themselves
  • Individuals who are not yet adults
  • Prisoners

Study Design

Enrollment

1001 participants

Anticipated

Intervention Model

Sequential

Primary purpose

Health Services Research

Interventions and Outcome Measures

Arms

experimental: Category 1 (biospecimens, surveys, interviews)

Cancer patients and survivors undergo collection of tissue, blood, saliva, and stool samples on study for genomic sequencing and microbiome analysis. Cancer patients and survivors also complete surveys and interviews on study pre and post intervention.

Interventions

Biospecimen Collection

Undergo collection of tissue, blood, saliva, and stool samples

Return of Results

Receive results

Survey Administration

Surveys and Interviews

Primary outcome measure

  • Total Enrolled Participants [ Time Frame: Up to 18 months ]
  • Data participation rate [ Time Frame: Up to 18 months ]
  • Biospecimen participation rate [ Time Frame: Up to 18 months ]
  • Rate of comprehensive genomic analysis completion [ Time Frame: Up to 18 months ]
  • Rate of successful return of clinical genetic/genomic results [ Time Frame: Up to 18 months ]
  • Rate of new threptic intervention as a result of participation [ Time Frame: Up to 18 months ]
  • Rate of Preparatory and Optimization Phase completion [ Time Frame: Up to 18 months ]

Central Contacts and Locations

Central contacts

Andrew Sussman, PhD

(505) 272-4077ASussman@salud.unm.edu

Kelsey Ayers, BS

1-833-795-0464KeAyers@salud.unm.edu

Locations

University of New Mexico Comprehensive Cancer Center

Recruiting

Albuquerque, New Mexico, United States, 87102

Contacts

Kelsey Ayers, BS

505-272-5062KeAyers@salud.unm.edu

More Information

Sponsor

New Mexico Cancer Research Alliance

Last update posted

Nov 13, 2025

Last verified

May, 2025

Keywords

  • PE-CGS
  • Southwestern Tribal Nations
  • Cancer Genome Sequencing
  • American Indians

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by New Mexico Cancer Research Alliance on 2025-11-13.